Gemmer Asset Management LLC Exelixis, Inc. Transaction History

Gemmer Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$17.44 - $23.16 $7,045 - $9,356	-404 Closed	0 $0
Q4 2021 Jan 21, 2022	BUY	$15.84 - $21.88 $1,298 - $1,794	82 Added 25.47%	404 $7,000
Q3 2021 Oct 19, 2021	SELL	$16.3 - $21.14 $2,819 - $3,657	-173 Reduced 34.95%	322 $7,000
Q2 2021 Jul 23, 2021	SELL	$17.95 - $25.56 $14,844 - $21,138	-827 Reduced 62.56%	495 $9,000
Q1 2021 Apr 20, 2021	BUY	$20.53 - $25.22 $20,530 - $25,220	1,000 Added 310.56%	1,322 $30,000
Q1 2020 May 01, 2020	BUY	$14.46 - $21.8 $1,402 - $2,114	97 Added 43.11%	322 $5,000
Q4 2019 Jan 17, 2020	SELL	$15.15 - $18.89 $469 - $585	-31 Reduced 12.11%	225 $4,000
Q3 2019 Oct 11, 2019	SELL	$17.68 - $22.65 $141 - $181	-8 Reduced 3.03%	256 $5,000
Q2 2019 Jul 18, 2019	SELL	$18.93 - $24.75 $1,514 - $1,980	-80 Reduced 23.26%	264 $6,000
Q4 2018 Jan 18, 2019	BUY	$13.65 - $21.8 $3,931 - $6,278	288 Added 514.29%	344 $7,000
Q3 2018 Oct 12, 2018	BUY	$15.87 - $22.4 $888 - $1,254	56 New	56 $1,000

460

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.57B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Gemmer Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Gemmer Asset Management LLC with notifications on news.